Parikh SA, Gale RP, Kay NE. Chronic lymphocytic leukemia in 2020: a surfeit of riches? Leukemia. 2020;34:1979–83.

Article  PubMed  PubMed Central  Google Scholar 

Munir T, Brown JR, O’Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319–32.

Article  CAS  PubMed  Google Scholar 

Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet. 2002;359:696–700.

Article  PubMed  Google Scholar 

Hróbjartsson A, Thomsen ASS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. CMAJ. 2013;185:E201–11.

Article  PubMed  PubMed Central  Google Scholar 

Brown JR, Eichhorst BF, Lamanna N, O’Brien SM, Tam CS, Qiu L, et al. Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL). Blood. 2023;142:202.

Article  Google Scholar 

Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharman JP, Egyed M, Jurczak W, Skarbnik AP, Kamdar MK, Munir T, et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. J Clin Oncol. 2022;40:7539.

Article  Google Scholar 

Munir T, Shadman M, Robak T, Brown JR, Kahl B, Ghia P, et al. P639: Zanubrutinib (ZANU) vs bendamustine + RITUXIMAB (BR) in patients (PTS) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll): extended follow-up of the sequoia study. Hemasphere. 2023;7:e15364af.

Article  PubMed Central  Google Scholar 

Ahn IE, Basumallik N, Tian X, Soto S, Wiestner A. Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood. 2019;133:2452–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Florez MA, Jaoude JA, Patel RR, Kouzy R, Lin TA, De B, et al. Incidence of primary end point changes among active cancer phase 3 randomized clinical trials. JAMA Netw Open. 2023;6:e2313819.

Article  PubMed  PubMed Central  Google Scholar 

Gale RP. Being certain even when you’re wrong: heuristics and thin slicing in haematopoietic cell transplantation. Bone Marrow Transpl. 2021;56:1223–6.

Article  Google Scholar 

https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf.

Das A, Lin TA, Lin C, Meirson T, McCaw ZR, Tian L, et al. Assessment of median and mean survival time in cancer clinical trials. JAMA Netw Open. 2023;6:e236498.

Article  PubMed  PubMed Central  Google Scholar 

Beauchemin C, Johnston JB, Lapierre MÈ, Aissa F, Lachaine J. Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis. Curr Oncol. 2015;22:e148–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gilboa S, Pras Y, Mataraso A, Bomze D, Markel G, Meirson T. Informative censoring of surrogate end-point data in phase 3 oncology trials. Eur J Cancer. 2021;153:190–202.

Article  PubMed  Google Scholar 

Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, et al. Long-term follow-up from A041202 shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024; blood.2023021959.

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020;395:1278–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36:1171–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

https://www.fda.gov/files/drugs/published/Multiple-Endpoints-in-Clinical-Trials-Guidance-for-Industry.pdf.

Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, Gormley N. Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival. J Clin Oncol. 2023;41:2706–12.

Article  PubMed  PubMed Central  Google Scholar 

Ghia P, Munir T, Burger J, Seymour J, Rogers K, Huang HH, et al. P645: ibrutinib for treatment of relapsed-refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison of 3 randomized phase 3 trials. Hemasphere. 2023;7:e78258de.

Article  PubMed Central  Google Scholar 

Amatya AK, Fiero MH, Bloomquist EW, Sinha AK, Lemery SJ, Singh H, et al. Subgroup analyses in oncology trials: regulatory considerations and case examples. Clin Cancer Res. 2021;27:5753–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5:1–56.

Article  CAS  PubMed  Google Scholar 

Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020;192:E901–E906.

Article  PubMed  PubMed Central  Google Scholar 

Haider H, Hoehn B, Davis S, Greiner R. Effective ways to build and evaluate individual survival distributions. J Mach Learn Res 2020;85:3289–351.

Google Scholar 

Agius R, Parviz M, Niemann CU. Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-art. Leuk Lymphoma. 2022;63:265–78.

Article  PubMed  Google Scholar 

Yang S, Kay NE, Shi M, Ossenkoppele G, Walter RB, Gale RP. Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both? Leukemia. 2021;35:3364–70.

Article  PubMed  Google Scholar 

Kipps TJ. Challenging the value of minimal residual disease in predicting outcome of patients with chronic lymphocytic leukemia. J Clin Oncol. 2023;41:3676–8.

Article  PubMed  Google Scholar 

Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O’Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021;138:2810–27.1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et al. S145: venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized cll14 study. Hemasphere. 2023;7:e064430a.

Article  PubMed Central  Google Scholar 

Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535–52.

Article  CAS  PubMed  Google Scholar 

Rosen K, Prasad V, Chen EY. Censored patients in Kaplan-Meier plots of cancer drugs: an empirical analysis of data sharing. Eur J Cancer. 2020;141:152–61.

Article  CAS  PubMed  Google Scholar 

Lesan V, Olivier T, Prasad V. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials. Eur J Cancer. 2024;202:114022.

Article  PubMed  Google Scholar 

Liang Y, Gale RP. Zanubrutinib in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1720.

PubMed  Google Scholar